Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis

Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis

Detalles Bibliográficos
Autores principales: Taylor, P, Blanco, R, Ikeda, K, Jia, B, Chen, YF, Walls, C, Haladyj, E, Fautrel, B
Formato: Conference item
Lenguaje:English
Publicado: BMJ Publishing Group 2021

Ejemplares similares